全文获取类型
收费全文 | 237539篇 |
免费 | 21816篇 |
国内免费 | 7537篇 |
专业分类
耳鼻咽喉 | 1762篇 |
儿科学 | 9318篇 |
妇产科学 | 4709篇 |
基础医学 | 21509篇 |
口腔科学 | 2943篇 |
临床医学 | 25231篇 |
内科学 | 34846篇 |
皮肤病学 | 3968篇 |
神经病学 | 14145篇 |
特种医学 | 4888篇 |
外国民族医学 | 13篇 |
外科学 | 17109篇 |
综合类 | 42456篇 |
现状与发展 | 32篇 |
一般理论 | 24篇 |
预防医学 | 16087篇 |
眼科学 | 3205篇 |
药学 | 18882篇 |
332篇 | |
中国医学 | 40755篇 |
肿瘤学 | 4678篇 |
出版年
2024年 | 1207篇 |
2023年 | 4784篇 |
2022年 | 8907篇 |
2021年 | 11803篇 |
2020年 | 11212篇 |
2019年 | 8573篇 |
2018年 | 8242篇 |
2017年 | 9273篇 |
2016年 | 9565篇 |
2015年 | 8923篇 |
2014年 | 18365篇 |
2013年 | 17768篇 |
2012年 | 16063篇 |
2011年 | 17463篇 |
2010年 | 13722篇 |
2009年 | 12294篇 |
2008年 | 11370篇 |
2007年 | 11559篇 |
2006年 | 9886篇 |
2005年 | 8286篇 |
2004年 | 6841篇 |
2003年 | 5865篇 |
2002年 | 4410篇 |
2001年 | 3966篇 |
2000年 | 3320篇 |
1999年 | 2877篇 |
1998年 | 2348篇 |
1997年 | 2126篇 |
1996年 | 1984篇 |
1995年 | 1783篇 |
1994年 | 1544篇 |
1993年 | 1305篇 |
1992年 | 1239篇 |
1991年 | 983篇 |
1990年 | 857篇 |
1989年 | 715篇 |
1988年 | 686篇 |
1987年 | 622篇 |
1986年 | 537篇 |
1985年 | 677篇 |
1984年 | 552篇 |
1983年 | 336篇 |
1982年 | 427篇 |
1981年 | 386篇 |
1980年 | 319篇 |
1979年 | 251篇 |
1978年 | 163篇 |
1977年 | 139篇 |
1976年 | 117篇 |
1975年 | 52篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
中药生产过程质量控制关键技术研究进展 总被引:10,自引:8,他引:2
中医药发展已上升到国家战略层面,在医药行业贯彻实施"中国制造2025"战略的新形势下,中药生产过程质量控制是中药工业需要加快突破的关键领域之一。对中药生产过程质量控制领域在工艺设计、分析检测、过程建模、制造装备等方面的关键共性问题进行解析,综述了中药生产过程质量控制体系中工艺过程理解、生产过程实时分析方法开发、过程控制策略建立3个方面的研究进展;并结合企业研究实践,介绍了质量源于设计(quality by design,Qb D)、过程分析技术(process analytical technology,PAT)、实验设计(design of experiment,DOE)、多变量统计分析等关键技术在上述3个研究方向中的应用进展,分析了实际工业应用的难点问题并对其应用前景进行展望,旨在为中药企业应用和提升生产过程质量控制技术提供参考。 相似文献
2.
3.
《Archives of Cardiovascular Diseases》2022,115(10):505-513
Central illustration: cumulative major adverse cardiac events (MACE) and bioresorbable vascular scaffold (BVS) thrombosis rates after 1, 2, 3, 4 and 5 years. 相似文献
4.
Alexandra Katsimardou Konstantinos Imprialos Konstantinos Stavropoulos Alexandros Sachinidis Michalis Doumas 《Expert opinion on pharmacotherapy》2020,21(10):1241-1252
ABSTRACT
Introduction
Type 1 diabetes mellitus (T1DM) is a chronic, autoimmune disease that is characterized by total absence of insulin production. Hypertension is a common comorbidity in T1DM with complex pathophysiology, while it is also a well-recognized risk factor for the development of cardiovascular disease (CVD), as well as other microvascular diabetic complications. 相似文献5.
6.
7.
《Mayo Clinic proceedings. Mayo Clinic》2022,97(12):2271-2281
ObjectiveTo investigate the association between type 1 diabetes mellitus (T1D) and type 2 diabetes mellitus (T2D) with risk of sudden cardiac arrest (SCA).MethodsIn a prospective community-based study of SCA from February 1, 2002, through November 30, 2019, we ascertained 2771 cases age 18 years of age or older and matched them to 8313 controls based on geography, age, sex, and race/ethnicity. We used logistic regression to evaluate the independent association between diabetes, T1D, T2D, and SCA.ResultsPatients had a mean age of 64.5±15.9 years, were 33.3% female and 23.9% non-White race. Overall, 36.7% (n=1016) of cases and 23.8% (n=1981) of controls had diabetes. Among individuals with diabetes, the proportion of T1D was 6.5% (n=66) among cases and 2.0% among controls (n=40). Diabetes was associated with 1.5-times higher odds of SCA. Compared with those without diabetes, the odds ratio and 95% CI for SCA was 4.36 (95% CI, 2.81 to 6.75; P<.001) in T1D and 1.45 (95% CI, 1.30 to 1.63; P<.001) in T2D after multivariable adjustment. Among those with diabetes, the odds of having SCA were 2.41 times higher in T1D than in T2D (95% CI, 1.53 to 3.80; P<.001). Cases of SCA with T1D were more likely to have an unwitnessed arrest, less likely to receive resuscitation, and less likely to survive compared with those with T2D.ConclusionType 1 diabetes was more strongly associated with SCA compared with T2D and had less favorable outcomes following resuscitation. Diabetes type could influence the approach to risk stratification and prevention of SCA. 相似文献
8.
9.
10.
《Vaccine》2019,37(31):4382-4391
Cancer-associated fibroblasts (CAFs), major components of the tumor microenvironment (TME), promote tumor growth and metastasis and inhibit the anti-tumor immune response. We previously constructed a DNA vaccine expressing human FAPα, which is highly expressed by CAFs, to target these cells in the TME, and observed limited anti-tumor effects in the 4T1 breast cancer model. When the treatment time was delayed until tumor nodes formed, the anti-tumor effect of the vaccine completely disappeared. In this study, to improve the safety and efficacy, we constructed a new FAPα-targeted vaccine containing only the extracellular domain of human FAPα with a tissue plasminogen activator signal sequence for enhanced antigen secretion and immunogenicity. The number of CAFs was more effectively reduced by CD8+ T cells induced by the new vaccine. This resulted in decreases in CCL2 and CXCL12 expression, leading to a significant decrease in the ratio of myeloid-derived suppressor cells in the TME. Moreover, when mice were treated after the establishment of tumors, the vaccine could still delay tumor growth. To facilitate the future application of the vaccine in clinical trials, we further optimized the gene codons and reduced the homology between the vaccine and the original sequence, which may be convenient for evaluating the vaccine distribution in the human body. These results indicated that the new FAPα-targeted vaccine expressing an optimized secreted human FAPα induced enhanced anti-tumor activity by reducing the number of FAPα+ CAFs and enhancing the recruitment of effector T cells in the 4T1 tumor model mice. 相似文献